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Long-term follow-up of an 8-year-old 
boy with insulinoma as the first 
manifestation of a familial form of 
multiple endocrine neoplasia type 1
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SUMMARY
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant hereditary cancer syn-
drome characterized mostly by parathyroid, enteropancreatic, and anterior pituitary tumors. We 
present a case of an 8-year-old boy referred because of hypoglycemic attacks. His diagnosis was 
pancreatic insulinoma. Paternal grandmother died due to repeated gastroduodenal ulcerations 
and a paternal aunt presented similar manifestations. At a first evaluation, the father presented 
only gastric ulceration but subsequently developed hyperparathyroidism and lung carcinoid 
tumor. During almost 15 years of follow-up, three brothers and the index case presented hyper-
parathyroidism and hyperprolactinemia. Molecular study showed a G to A substitution in intron 
4, at nine nucleotides upstream of the splicing acceptor site, causing a splicing mutation. All 
affected members of the family have the same mutation. Paternal grandmother and aunt were 
not studied and the mother does not carry any mutation. MEN1 is a rare condition that requires 
permanent medical assistance. Early clinical and genetic identification of affected individuals 
is essential for their own surveillance and also for genetic counseling. Arq Bras Endocrinol Metab. 
2010;54(8):754-60
SUMÁRIO
A neoplasia endócrina múltipla tipo 1 (NEM1) é uma doença hereditária autossômica domi-
nante, caracterizada principalmente por tumores de paratireoide, enteropancreáticos e adeno-
-hipofisários. Apresentamos o caso de um menino com 8 anos encaminhado por crises de 
hipoglicemia. Seu diagnóstico foi insulinoma pancreático. Sua avó paterna faleceu por úlceras 
gastroduodenais de repetição e a tia paterna tinha as mesmas manifestações. Na primeira 
avaliação, o pai apresentou apenas úlcera gástrica, porém com a evolução desenvolveu hiper-
paratireoidismo e tumor carcinoide pulmonar. Durante cerca de 15 anos de seguimento, os três 
irmãos e o caso índice desenvolveram hiperparatireoidismo e hiperprolactinemia. O estudo 
molecular mostrou a substituição G por A no intron 4, a nove nucleotídeos do sítio aceptor de 
splicing, criando um novo sítio de splicing. Todos os membros da família afetados e estudados 
tinham a mesma mutação. A NEM1 é uma condição rara que requer assistência médica per-
manente. As identificações clínicas e genéticas precoces são essenciais para o tratamento e 
aconselhamento genético. Arq Bras Endocrinol Metab. 2010;54(8):754-60
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INTRODUCTION
Multiple endocrine neoplasia type 1 (MEN1 – OMIM 131100) is an autosomal dominant 
familial cancer syndrome characterized by primary 
hyperparathyroidism in association with endocrine en-
teropancreatic tumors and anterior pituitary adenomas, 
but manifestations of carcinoid tumors, adrenal adeno-
mas, and lipomas are also reported. The occurrence of 
two MEN1-related endocrine tumors is sufficient to es-
tablish the clinical diagnosis (1-3). This syndrome often 
occurs at a young age with equal sex distribution (3). 
Primary hyperparathyroidism is responsible for more 
than 90% of clinical cases and usually it is the first clini-
cal manifestation of MEN1. Enteropancreatic tumors 
(gastrinomas, glucagonomas, VIPomas, insulinomas, 
or non-functioning tumors) affect about 30%-80% of 
patients (4), while the incidence of pituitary adenomas 
(prolactinomas, somatotropinomas, corticotropino-
mas, or non-functioning tumors) in MEN1 patients 
varies from 15% to 90% (5-6).
The MEN1 gene, which is responsible for the dis-
ease, is located on 11q13, occupies 9.8 kb of genomic 
DNA, and encodes a 610-aminoacid protein called me-
nin, within 10 exons (7). It is considered to be a tumor 
suppressor gene by altering JunD-mediated transcrip-
tion (8). It is involved in the regulation of cell functions 
such as DNA replication and repair, and also in the 
transcriptional machinery (7,9,10). MEN1 mutations 
have a high degree of penetrance: more than 95% of pa-
tients who carry a mutation will develop the disease by 
the fifth decade of life (3), however, the phenotype is 
highly variable therefore a direct genotype-phenotype 
correlation has been difficult to be established (11). 
Carriers of MEN1 gene mutations may benefit from 
periodic clinical evaluations (12). Generally, MEN1 
germline mutations are identified with a prevalence av-
erage of 70% in the familial forms, whereas the sporadic 
cases, associated with de novo mutation in the MEN1 
gene, represents about 5%-10% (13). More than 1,000 
MEN1 mutations have been reported; about 25% are 
nonsense, 45% intragenic deletions, 15% insertions, 
10% missense mutations, and less than 5% are splice site 
mutations (14).
Herein we report an unusual index case presenting 
with hypoglycemia in early age (8 years of age) within a 
MEN1 family. Long-term follow-up with clinical mani-
festations and management of all affected relatives are 
also discussed. 
CASE REPORT 
Clinical data 
An 8-year-old boy was admitted at our pediatric clinic 
because of seizures misdiagnosed as epilepsy (normal 
EEG and cerebral CT). He also had sweating, palpi-
tation, tremulousness, hunger, anxiety, and a sudden 
weight gain (8 kg in 4 months). Laboratory data con-
firmed hyperinsulinemic hypoglycemia (glycemia = 19 
mg/dL – Normal range – NR = 60-99; insulinemia = 
26.2 IU/mL – NR < 5; and C-peptide = 3.2 ng/mL – 
NR = 1.1-5.0). Pancreatic angiography and abdomen 
CT suggested nodules in the pancreas region. Upon 
intraoperative ultrasound two lesions in the distal body 
of the pancreas were observed (0.6 cm and 0.3 cm in 
size); they were removed by partial pancreatectomy. 
Histological analysis confirmed insulinoma, and immu-
nohistochemistry examination was also strongly posi-
tive for insulin but also slightly positive for glucagon 
and gastrin (Figure 1 A-D). 
To date, his family history includes a healthy mother 
and 3 brothers (an older boy and two younger twins). 
In addition, his paternal grandmother had repeated 
gastroduodenal ulceration and urolithiasis since the 
age of 38 and died at the age of 45 due to gastric ul-
cer perforation. Autopsy showed peptic ulcer with 
gastrin-secreting duodenal mucosa tumor (gastrinoma 
– Zollinger-Ellison syndrome) and primary hyperpara-
thyroidism. His paternal aunt also had repeated gas-
troduodenal ulceration and urolithiasis, and his father 
presented only gastroduodenal ulceration when he was 
first examined. 
The patient had been clinically stable during sev-
eral years of follow-up and showed normal growth and 
puberty. However, at the age of 16 he also presented 
elevated PTH (90.9 pg/mL, NR = 10.0-50.0) and cal-
cium (11.1 mg/dL – NR = 8.5-10.5) leading to pri-
mary hyperparathyroidism diagnosis and subsequently 
to subtotal parathyroidectomy. He is now 25 years old, 
without symptoms, MRI of the pituitary region is nor-
mal and prolactin high (54.3 ng/mL – NR < 15); PTH 
and calcium serum concentrations have been main-
tained in the upper normal range throughout 5 years; 
and, both glycemia and insulin are normal. 
During 15 years of family follow-up, his father 
showed primary hyperparathyroidism. In the preop-
erative evaluation for subtotal parathyroidectomy a 
bronchial carcinoid tumor was identified in the chest 
radiography. Both tumors were surgically treated and 
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Figure 1. (A) HE-50X: The arrow indicates a hypercellular pancreatic nodule with thin capsule. (B) HE-400X: Polygonal cells in a solid, trabecular and 
glandular pattern, with no atypia or necrosis. (C) Immunohistochemical assay demonstrating intense and diffuse positivity for insulin. (D) ultrastructural 
study showing neuroendocrine granules.
A
C
B
D
chemotherapy was performed after lobectomy. He is 
now 51 years old and is doing well with normal serum 
levels of PTH, calcium, glucose, insulin and prolactin. 
A 29-year-old brother reported hyperprolactinemia 
due to a pituitary macroadenoma when he was 24 years 
old. Since then he has been successfully treated with 
cabergoline. One year later, he developed primary hy-
perparathyroidism; therefore, he underwent subtotal 
parathyroidectomy. The two 23-year-old younger twin 
brothers presented different symptoms. One developed 
hyperinsulinemic hypoglycemia due to insulinoma at 
the age of 18 and underwent subtotal pancreatectomy. 
Histological analysis confirmed multiple pancreatic 
nodules and immunohistochemistry examination was 
positive for insulin and negative for glucagon and gas-
trin. One year later, he developed diabetes and started 
insulin replacement. At the age of 20, he had hyperp-
rolactinemia that was treated with cabergoline and after 
other year he showed elevated PTH and calcium indi-
cating subtotal parathyroidectomy. The other twin had 
elevated PTH and calcium when he was 18 years old; 
therefore subtotal parathyroidectomy was performed. 
Two years later he presented hyperprolactinemia treat-
ed with cabergoline. Father and brothers remain un-
der treatment and periodic screening, which consists of 
medical appointments taking place twice a year, labo-
ratorial investigation performed annually and imaging 
studies conducted every two years (Table 1). 
Molecular analysis
Blood specimens of the patient and his relatives were 
collected with approval by the appropriate institutional 
review board and a signed informed consent was ob-
tained.
Genomic DNA from peripheral blood leukocytes 
was purified by proteinase K digestion and phenol/
chloroform extraction followed by ethanol precipita-
tion using standard techniques (15). The 10 exons and 
the exon-intron junction regions of the MEN1 gene 
were PCR-amplified from genomic DNA with spe-
cific primers designed using GenRunner free software 
(Table 2). MEN1 gene sequence was obtained in the 
ENSEMBL database (ENSG00000133895 − www.en-
sembl.org).
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Table 1. Clinical data, management and follow-up of MEN1 manifestations in all cases of the Brazilian family studied
Patient Manifestation Age at diagnosis Management Follow-up
Time of 
follow-up
Index case Hypoglycemia (insulinoma) 8 Partial pancreatectomy Normal insulin and glycemia 17
Primary hyperparathyroidism 16 Subtotal parathyroidectomy upper normal range of PTH and calcium
Hyperprolactinemia (normal MRI) 25 Observation Moderate hyperprolactinemia
Paternal grandmother Repeated gastroduodenal 
ulceration and urolithiasis 
38 NR Died at 45 years-old due to gastric 
perforation (gastrinoma) 
-
Paternal aunt Repeated gastroduodenal 
ulceration and urolithiasis
NR NR NR NR
Father Gastroduodenal ulceration 35 Clinical treatment Without symptoms 17
Primary hyperparathyroidism 45 Subtotal parathyroidectomy Normal PTH and calcium
Bronchial carcinoid 45 Lobectomy + chemotherapy Without symptoms 
Older brother Hyperprolactinemia 
(macroadenoma)
24 Cabergoline treatment Normal prolactin 5
Primary hyperparathyroidism 25 Subtotal parathyroidectomy Normal PTH and calcium
Younger brother (twin A) Hypoglycemia (insulinoma) 18 Near-total pancreatectomy Insulin-dependent diabetes 5
Hyperprolactinemia (normal MRI) 20 Cabergoline treatment Normal prolactin
Primary hyperparathyroidism 21 Subtotal parathyroidectomy Normal PTH and calcium
Younger brother (twin B) Primary hyperparathyroidism 18 Subtotal parathyroidectomy Normal PTH and calcium 5
Hyperprolactinemia (normal MRI) 20 Cabergoline treatment Normal prolactin
NR: not reported. 
Table 2. Primers designed for amplification and sequencing of MEN1 gene
Primer Sequence (5’-3’) Tm (ºC)1 Size (bp)2
5’uTRs CCCCGAGTCTGCAGGTAGTG 61.8 801
Ex 2as AGCTCGGCAGCAAACAGG 60.6 801
Int 1s AACCTTAGCGGACCCTGGG 63 705
Int 2as GCATATCATTTCCCCTCTCTGG 62.4 705
Int 2s CCCCATGTTAAAGCACAGAGG 61.6 720
Int 4as ACTAACCCATTTTTCCAGGAGG 61.6 720
Int 4s CTTTCCCTTCCTGAGCTTCAG 60.3 596
Int 6as ACACAAAGTGAGACTGGATGGG 60.4 596
Int 6s TGGGAGTGGAGATGGAGAGG 60.6 956
Int 8as ATCCCTAATCCCGTACATGCAG 58 956
Int 7s3 TCCTTTCTTCCCCTCCATCAG 62.4
Int 7as3 ACTGGATGGAAAGGGGATG 58
Int 8s CTGGCTATGGATTGGCTTTATA 59.4 486
Int 9as AGCAAGGTGAGAGCAAGGTTG 61.2 486
Int 9s TGGGTGGGATGGGATGG 60.1 711
3’uTRas AGGGTTTGGGTAGAGGTGAGG 61.6 711
Ex 10s3 ACTGGACAAGGGCCTGGG 61.3
Ex 10as3 AGTTGCAGCTTGATGGCG 58.7
1: annealing temperature used in PCR; 2: size of amplified fragments; 3: internal primers used for 
sequencing purposes.
All coding regions and their adjacent sequences 
of the MEN1 gene from the four brothers and their 
parents were amplified and sequenced. The molecular 
analyses identified the heterozygous G>A nucleotide 
change in the splice acceptor region of intron 4 (IVS4-
9G>A) in all brothers and the father (Figure 2 A-C). 
The mother did not carry the mutation; and the pater-
nal grandmother and aunt were not tested. Heterozy-
gosis for single nucleotide polymorphisms (SNPs) were 
identified as described in table 3.
DISCUSSION
Clinical manifestations of MEN1-associated diseases 
are very rare in childhood (14) and the overall preva-
lence of insulinoma is almost 10% (3). Primary hyper-
parathyroidism is the most common endocrinopathy in 
MEN1, reaching nearly 100% penetrance by the age 
of 50 years (3). Urolithiasis is usually the first manifes-
tation of hyperparathyroidism associated with MEN1 
and it affects about 30% to 75% of the cases (16).
In the present paper, MEN1-associated insulinoma 
was first suspected based on the familial history of pa-
ternal grandmother and aunt, and was confirmed after 
histological analysis. Genetic testing is strongly recom-
mended in familial cases of Zollinger-Ellison syndrome 
since they are almost exclusively seen in MEN1 pa-
tients (17). In the family reported here, genetic testing 
showed that the father and all siblings were carriers of 
the IVS4-9G>A mutation. The long-term follow-up of 
Familial form of multiple endocrine neoplasia 1
Co
py
rig
ht
©
 A
BE
&
M
 to
do
s o
s d
ire
ito
s r
es
er
va
do
s.
758 Arq Bras Endocrinol Metab. 2010;54/8
A
B
C
Figure 2. Sequence analysis showing the IVS4-9G>A mutation. Sequences boxed correspond to the first nucleotides of exon 5 and the arrow indicates the 
nucleotide change. (A) Heterozygous G to A substitution detected in blood DNA of the patient. (B) DNA from his normal mother. (C) Family pedigree. The 
arrow indicates the index-case. Asterisks indicate individuals that were personally analyzed. E+(IVS4-9G>A) and E-(IVS4-9G>A) denote that the individuals 
have been molecularly evaluated for the mutation and are, respectively, heterozygous and normal homozygous. Individuals I.2 and II.1 were not molecularly 
analyzed but clinical data indicated MEN1 manifestation. 
all affected members showed variable clinical manifesta-
tions, with early onset (from 8 to 24 years of age) in all 
the brothers. 
Among enteropancreatic tumors, gastrinomas are 
the most common and the major cause of morbidity 
and mortality, as occurred in the paternal grandmother. 
They are often multiple and present high risk of me-
tastasis. Conversely, insulinomas are usually benign and 
surgery tends to be curative (18). Non-functional enter-
opancreatic tumors may appear in the first two decades 
of life and present risk of malignancy. Medical conduct 
already recommends to begin screening for enteropan-
creatic tumors, especially for insulinoma, at the age of 5 
years (3,18). Nowadays, this recommendation has been 
extended to the non-functioning tumors as well (4).
To our knowledge, this is the second report describ-
ing clinical symptoms and genetic testing in twins with 
MEN1. Similarly to the case reported by Rix and cols. 
(19), the twin brothers presented different phenotypes, 
with primary hyperparathyroidism and hyperprolac-
tinemia in both, but only one developed insulinoma. 
Variability in phenotypes may reflect a random chance 
for a second mutation in susceptible cells with loss of 
heterozygosity, in accordance with Knudson’s “two 
hit” hypothesis (7,14). Some of the affected individuals 
described here are heterozygous for frequent SNPs in 
MEN1 gene. The p.D418D polymorphism caused by 
the c.1269C>T nucleotide change in exon 9 was found 
in the father and in individuals III-1 and III-4. This 
polymorphism has previously been associated with spo-
radic hyperparathyroidism (20) and it was found to be 
more frequent in Brazilian patients than in those stud-
ied in the USA and Europe (21). In the present study 
hyperparathyroidism was diagnosed in five affected in-
dividuals but only three carry the p.D418D polymor-
phism, therefore it seems that hyperparathyroidism and 
p.D418D are not associated in those cases. Whereas, 
other polymorphisms have been identified (Figure 
1D), if combined to specific haplotypes we found that 
the “TACC” haplotype (c.-35A>T>C, c.799-9G>A, 
Familial form of multiple endocrine neoplasia 1
Table 3. Heterozygosis for SNPs and c.799-9G>A mutation in MEN1 family
5’UTR Intron 4 Exon 9 Intron 9
SNP access number rs679946 mutation rs2071313 rs654440
cDNA position c.-35A>C>T c.799-9G>A c.1269C>T c.1365+103C>G
II-2 A/T G/A C/T C/G
II-3 T/T G/G C/C C/C
III-1 T/C G/A C/T C/G
III-2 T/T G/A C/C C/C
III-3 T/T G/A C/C C/C
III-4 T/C G/A C/T C/G
 
I
II
III
1 2
1 2
* *
****
3 4
4321
E+(IVS4-9G>A) E+(IVS4-9G>A)
E+(IVS4-9G>A) E-(IVS4-9G>A)
E+(IVS4-9G>A)
5
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c.1269C>T, and c.1365+103C>G) is present in the 
individuals who developed insulinoma. Two other hap-
lotypes were identified: “CAGT” in two brothers and 
probably “TATG” in the father. Since all siblings carry 
the IVS4-9G>A mutation inherited from the father, 
it is very difficult to find an explanation for such dif-
ferences within the MEN1 gene. Possible mechanisms 
might involve double independent events generating 
germline mosaicism. 
In late onset heritable disorders, the benefits of 
genetic diagnosis must be balanced with the psycho-
logical effects of the screening procedure. As no cu-
rative treatment can be offered to carriers of MEN1 
gene mutations, early detection will be positive for the 
possibility of initiating adequate treatment at a pres-
ymptomatic stage, which may decrease morbidity and 
mortality (12,21,22). Therefore, parents within fami-
lies with a clinical diagnosis of MEN1 should receive 
genetic counseling in order to be able to decide about 
genetically testing their children. 
The earliest presentation of an endocrine tumor in 
MEN1 reported in the literature was an aggressive pro-
lactin and GH-secreting pituitary macroadenoma in a 
5-year-old boy (23). Pancreatic insulinoma has been 
described in a 7-year-old boy (24), followed by primary 
hyperparathyroidism at the age of 8 years (3). Our in-
dex patient showed an insulinoma when he was 8 years 
old, reinforcing the proposition that a clinical screening 
program for children carrying MEN1 gene mutations 
should start at the age of 10-15 years (21,22,25,26). 
These children should be evaluated with annual blood 
tests by measuring serum calcium, pancreatic polypep-
tide and gastrin, prolactin and insulin-like growth fac-
tor-1. Annual pancreatic ultrasound, and pancreatic 
and pituitary MRI every 3-5 years, should also be per-
formed. A consensus statement from 2001 (3) recom-
mended that screening should begin at 5 years of age as 
mentioned above. 
Several germline MEN1 gene mutations have been 
described in Brazilian patients (21,27) and they are 
mainly frameshift, nonsense or missense mutations. 
The G>A substitution at 9 nucleotides upstream from 
the splicing junction of the MEN1 gene in intron 4, 
described before in European and Japanese patients 
(28,29), is reported here for the first time in a Brazil-
ian family. The IVS4-9G>A that was first described as 
a polymorphism with heterozygosity frequency of 3% 
(30), however, it was further demonstrated to produce 
two different transcripts. The most abundant transcript 
presented an insertion of seven nucleotides in the exon 
4 and 5 junction, and the less abundant had a normal 
mRNA sequence (29). Therefore, it was associated to 
MEN1 phenotype in an European adult patient with 
adrenocortical adenoma and lung carcinoid tumor (28) 
and also in three Japanese adult patients from two un-
related families, but with different phenotypes. The 
different phenotypes were: one with hyperparathyroid-
ism, repeated gastroduodenal ulceration, subcutaneous 
lipoma and insulinoma; the other two sisters presented 
hyperparathyroidism, whereas only one had insulinoma 
(29). Our index case also had insulinoma and hyper-
parathyroidism, however, the manifestations were ob-
served earlier than those previously reported. In all cas-
es this alteration was described as a germline mutation. 
In conclusion, the early diagnose and the long-term 
follow-up of the MEN1 family described in the present 
paper reinforces that careful family history with regards 
to familial MEN1 should always be investigated in pa-
tients presenting with insulinoma in childhood. Addi-
tionally, the possibility of confirming MEN1 diagnosis 
by genetic testing should be offered to the children and 
their families. 
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